Tumor-associated Antigens from GeneTex

July 6, 2015 - PRLog -- In an excellent Nature Reviews Cancer "Perspectives" discussion, Coulie et.al. (2014) construct a timeline of seminal discoveries that established the framework for our present understanding of tumor rejection antigens and their recognition by cytotoxic T lymphocytes (CTLs). The authors highlight the notion of an immunosuppressive environment existing in tumors that reinforces CTL hyporesponsiveness. They suggest therapeutic vaccination, perhaps in conjunction with inhibitors of immunosuppression, could establish a local immunostimulatory milieu in the tumor that would facilitate activation of CTLs reactive to the vaccine antigen in addition to those CTLs that target other tumor antigens.

GeneTex offers an excellent selection of antibodies for the study of tumor immunology. We strive to serve and accelerate life science research by creating essential biomedical reagents where quality can be found in every vial. Please see our highlighted products below  for our complete catalog of tumor-associated antigens.

MUC1 antibody (GTX100459): http://www.genetex.com//MUC1-antibody-GTX100459.html